09:50 AM EST - Helix BioPharma Corp. : reported third-quarter net loss of $4.20 million, slightly wider than last year's $4.13 million. However, loss per common share narrowed to $0.07 from $0.08 a year ago. Quarterly revenues totaled $1.11 million, representing an increase of 20.6% from last year. Product revenues totaled $933,000, while license fees and royalties amounted to $181,000. The company reported research and development costs of $3.14 million, compared to $3.08 million last year. Helix BioPharma Corp.
shares T.HBP are trading even at $2.37.
